All News
JAK/STAT pathway in pyoderma gangrenosum: a new therapeutic highway?
Pyoderma gangrenosum (PG) is rare, but often associated with different forms of arthritis, in particular rheumatoid arthritis and inflammatory bowel diseases.
Read ArticleSpondyloarthritis and COVID-19
There are still questions surrounding COVID-19, and some common questions I receive from patients revolve around what to do with their current DMARDs or should they even start treatment during this pandemic. Two studies focused on this question.
Read ArticleLinks:
ACR Applauds FTC Decision to Investigate PBM's
The American College of Rheumatology applauds the Federal Trade Commission’s decision to investigate the business practices of pharmacy benefit managers (PBMs), which continue to increase PBM profit margins while placing the burden of skyrocketing drug costs on America’s most vulnerable patients,
Read ArticleLinks:
CV risk factors not equal when considering magnitude of risk
What can we learn from Oral Surveillance?
The Oral Surveillance trial has almost become a household word for rheumatologists.
Read ArticleTime to consider gender stratification in AxSpA diagnosis and management
Differences across genders in many aspects related to rheumatic diseases diagnosis, phenotyping, trajectories definition and prediction of response to treatment have been overlooked.
Read ArticleUpdate on Axial SpA at EULAR 2022
This year at EULAR 2022, there were important and interesting topics in Axial Spondyloarthritis (AxSpA). These are my picks of abstracts from the conference.
Read ArticleMalignancy risk on b/tsDMARDs in patients with prior malignancy history
For autoimmune patients with a history of malignancy, the initiation of biologic or targeted synthetic disease modifying agents (bDMARD/tsDMARDs) may provoke concern.
Read ArticleLinks:
Janet Pope Janetbirdope ( View Tweet)
Links:
Robert B Chao, MD doctorRBC ( View Tweet)
Links: